Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Share-based Compensation (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Share-based Compensation for 9 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 17.68% to $10.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.0 million through Dec 2025, up 22.42% year-over-year, with the annual reading at $46.0 million for FY2025, 22.42% up from the prior year.
  • Share-based Compensation hit $10.7 million in Q4 2025 for Protagonist Therapeutics, up from $10.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.8 million in Q1 2025 to a low of $2.7 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $7.7 million across 5 years, with a median of $7.2 million in 2022.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 155.41% in 2021 and later rose 3.88% in 2025.
  • Year by year, Share-based Compensation stood at $5.0 million in 2021, then increased by 9.71% to $5.5 million in 2022, then increased by 19.76% to $6.6 million in 2023, then skyrocketed by 37.75% to $9.1 million in 2024, then increased by 17.68% to $10.7 million in 2025.
  • Business Quant data shows Share-based Compensation for PTGX at $10.7 million in Q4 2025, $10.6 million in Q3 2025, and $10.9 million in Q2 2025.